Portal:CPTAC/FeaturedPathways
From WikiPathways
(Difference between revisions)
(Added pancreatic cancer pw) |
Current revision (21:46, 26 May 2020) (view source) (Added WP4806) |
||
| (10 intermediate revisions not shown.) | |||
| Line 10: | Line 10: | ||
|width=100px|{{#pwImage:Pathway:WP585|250px||Interferon type I signaling pathways}} | |width=100px|{{#pwImage:Pathway:WP585|250px||Interferon type I signaling pathways}} | ||
|width=100px|{{#pwimage:Pathway:WP3|250px||Transcriptional activation by NRF2}} | |width=100px|{{#pwimage:Pathway:WP3|250px||Transcriptional activation by NRF2}} | ||
| - | |||
| - | |||
| - | |||
| - | |||
|width=100px|{{#pwImage:Pathway:WP4204|250px||Tumor suppressor activity of SMARCB1}} | |width=100px|{{#pwImage:Pathway:WP4204|250px||Tumor suppressor activity of SMARCB1}} | ||
| - | |||
|- | |- | ||
| + | |width=100px|{{#pwimage:Pathway:WP4018|250px||Pathways in clear cell renal cell carcinoma}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4205|250px||MET in type 1 Papillary renal Cell Carcinoma}} | ||
|width=100px|{{#pwImage:Pathway:WP4206|250px||Hereditary Leiomyomatosis and Renal Cell Carcinoma Pathway}} | |width=100px|{{#pwImage:Pathway:WP4206|250px||Hereditary Leiomyomatosis and Renal Cell Carcinoma Pathway}} | ||
| + | |width=100px|{{#pwImage:Pathway:WPWP4241|250px||Type 2 papillary renal cell carcinoma}} | ||
| + | |- | ||
|width=100px|{{#pwImage:Pathway:WP4216|250px||Chromosomal and microsatellite instability in colorectal cancer}} | |width=100px|{{#pwImage:Pathway:WP4216|250px||Chromosomal and microsatellite instability in colorectal cancer}} | ||
|width=100px|{{#pwImage:Pathway:WP4239|250px||EMT transition in Colorectal Cancer}} | |width=100px|{{#pwImage:Pathway:WP4239|250px||EMT transition in Colorectal Cancer}} | ||
|width=100px|{{#pwImage:Pathway:WP4240|250px||Regulation of sister chromatid separation at the metaphase-anaphase transition}} | |width=100px|{{#pwImage:Pathway:WP4240|250px||Regulation of sister chromatid separation at the metaphase-anaphase transition}} | ||
| - | |||
|width=100px|{{#pwImage:Pathway:WP4258|250px||LncRNA involvement in canonical Wnt signaling and colorectal cancer}} | |width=100px|{{#pwImage:Pathway:WP4258|250px||LncRNA involvement in canonical Wnt signaling and colorectal cancer}} | ||
| + | |- | ||
|width=100px|{{#pwImage:Pathway:WP4255|250px||Non-small cell lung cancer}} | |width=100px|{{#pwImage:Pathway:WP4255|250px||Non-small cell lung cancer}} | ||
|width=100px|{{#pwImage:Pathway:WP4263|250px||Pancreatic adeonocarcinoma pathway}} | |width=100px|{{#pwImage:Pathway:WP4263|250px||Pancreatic adeonocarcinoma pathway}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4262|250px||Breast cancer pathway}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4155|250px||Endometrial cancer}} | ||
| + | |- | ||
| + | |width=100px|{{#pwImage:Pathway:WP4290|250px||Metabolic reprogramming in colon cancer}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP3301|250px||MFAP5-mediated ovarian cancer cell motility and invasiveness}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4582|250px||Cancer immunotherapy by CTLA4 blockade}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4585|250px||Cancer immunotherapy by PD-1 blockade}} | ||
| + | |- | ||
| + | |width=100px|{{#pwImage:Pathway:WP4658|250px||Small cell lung cancer}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4666|250px||Hepatitis B infection}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4674|250px||Head and Neck Squamous Cell Carcinoma}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4806|250px||EGFR Tyrosine Kinase Inhibitor Resistance}} | ||
|} | |} | ||
Current revision
|
Image does not exist TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer |
Image does not exist PDGFR-beta pathway Zhang, et al. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer |
Image does not exist Bladder Cancer |
Image does not exist EPO Receptor Signaling |
|
Image does not exist ErbB Signaling Pathway |
Image does not exist Interferon type I signaling pathways |
Image does not exist Transcriptional activation by NRF2 |
Image does not exist Tumor suppressor activity of SMARCB1 |
|
Image does not exist Pathways in clear cell renal cell carcinoma |
Image does not exist MET in type 1 Papillary renal Cell Carcinoma |
Image does not exist Hereditary Leiomyomatosis and Renal Cell Carcinoma Pathway |
Image does not exist Type 2 papillary renal cell carcinoma |
|
Image does not exist Chromosomal and microsatellite instability in colorectal cancer |
Image does not exist EMT transition in Colorectal Cancer |
Image does not exist Regulation of sister chromatid separation at the metaphase-anaphase transition |
Image does not exist LncRNA involvement in canonical Wnt signaling and colorectal cancer |
|
Image does not exist Non-small cell lung cancer |
Image does not exist Pancreatic adeonocarcinoma pathway |
Image does not exist Breast cancer pathway |
Image does not exist Endometrial cancer |
|
Image does not exist Metabolic reprogramming in colon cancer |
Image does not exist MFAP5-mediated ovarian cancer cell motility and invasiveness |
Image does not exist Cancer immunotherapy by CTLA4 blockade |
Image does not exist Cancer immunotherapy by PD-1 blockade |
|
Image does not exist Small cell lung cancer |
Image does not exist Hepatitis B infection |
Image does not exist Head and Neck Squamous Cell Carcinoma |
Image does not exist EGFR Tyrosine Kinase Inhibitor Resistance |
